Listed

KALA BIO, Inc.: Form 10-Q for the period ended Mar 31, 2024

Filed with the SEC on May 14, 2024 and accepted by EDGAR at May 14, 2024, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2024-01-01 to 2024-03-31$6.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2024-01-01 to 2024-03-31−$11.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-01-01 to 2024-03-31$1.5mus-gaap:InterestExpense
Net income3 months2024-01-01 to 2024-03-31−$11.8mus-gaap:NetIncomeLoss
Basic EPS3 months2024-01-01 to 2024-03-31−$4.20us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-01-01 to 2024-03-312,813,210 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2024-01-01 to 2024-03-31−$10.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2024-03-31$48.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-03-31$50.1mus-gaap:AssetsCurrent
Total assetsAt period end2024-03-31$53.0mus-gaap:Assets
Current liabilitiesAt period end2024-03-31$11.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-03-31$46.4mus-gaap:Liabilities
Long-term debtAt period end2024-03-31$28.5mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-03-31$6.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-03-31$6.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-24-008134. Last ingested by Listed: Nov 3, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.